Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DDC antisense RNA 1 (DDC-AS1) is a long non-coding RNA transcribed in an antisense orientation to the DDC (Aromatic L-Amino Acid Decarboxylase) gene[3][5]. As with other antisense RNAs, it is thought to regulate gene expression by mechanisms such as transcriptional interference, modification of chromatin state, or stabilization/destabilization of sense mRNA[1][2][4]. DDC-AS1 is primarily classified as a lncRNA, and there is limited functional or translational data directly linking this transcript to therapeutic targeting or as a biomarker. Associations have been made with Aromatic L-Amino Acid Decarboxylase Deficiency, but its direct mechanistic involvement remains unclear[3]. Like other antisense RNAs, it could potentially contribute to gene regulation in both normal physiology and disease, though detailed functional studies for DDC-AS1 are lacking[1][3].
No drugs specifically target DDC-AS1; however, in general, antisense RNAs can be modulated by antisense oligonucleotides, leading to RNase H-mediated RNA degradation or modulation of RNA processing[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DDC antisense RNA 1 (DDC-AS1).